US drugmaker Pfizer has said it had raised its offer for British rival AstraZeneca to £55 a share and increased the cash element to 45 percent.
AstraZeneca rejected an earlier of cash-and-stock approach worth £50 a share on May 2, arguing it substantially undervalued the company.
Pfizer has until Monday until it admits defeat in bidding for AstraZeneca. But after the shenanigans of the past few days we cannot be sure.
AstraZeneca's share price is tumbling back down to earth after the board rejected a "final" Pfizer bid. So is the takeover really over?
Sweden's Finance Minister says the Government should be "very, very sceptical" about any promises the US pharmaceutical giant makes.